Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
Immunotherapy Advances · 01.01.2023 · 3 (1)
DOI: 10.1093/immadv/ltad026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 22.11.2023. Verfasst von Katie R Flaherty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, King's College London, London, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immunotherapy treatment strategies have proven effective in a limited portion of patients, where identifying responders from non-responders to treatment remains a challenge. While some indications can be drawn from invasive biopsies, we need more accessible methods for predicting response and better correlates of response prior to starting therapy. Recent work has identified differences in immune composition at baseline in peripheral blood from melanoma patients responding to PD-1 blockade treatment. Through flow cytometric analysis of T cell receptors, phenotypical features of CD8+ and CD4+ T cells and Tregs could allow for the stratification of treatment response. Analysing T cells within peripheral blood could potentially allow for the stratification of PD-1 treatment response prior to therapy in different cancer settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, King's College London, London, UK.
- Institute of Immunity and Transplantation, University College London, London, UK.
- William Harvey Research Institute, Queen Mary University of London, London, UK.
- National Heart and Lung Institute, Imperial College London, London, UK.
ORCID-Profile: George E Finney
Zitieren
APA
Flaherty, K. R., Kucykowicz, S., Schroth, J., Traves, W., Mincham, K. T., & Finney, G. E. (2023). Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?. Immunotherapy Advances, 3(1). https://doi.org/10.1093/immadv/ltad026
Vancouver
Flaherty KR, Kucykowicz S, Schroth J, Traves W, Mincham KT, Finney GE. Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?. Immunotherapy Advances. 2023;3(1). doi:10.1093/immadv/ltad026
BibTeX
@article{Flaherty2023,
author = {Flaherty, Katie R and Kucykowicz, Stephanie and Schroth, Johannes and Traves, Will and Mincham, Kyle T and Finney, George E},
title = {Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?},
journal = {Immunotherapy Advances},
year = {2023},
volume = {3},
number = {1},
doi = {10.1093/immadv/ltad026}
}
EUVIMED